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The crystal structure of the human A2A adenosine receptor
bound to the A2A receptor-specific antagonist, ZM241385, was
recently determined at 2.6-A˚ resolution. Surprisingly, the
antagonist binds in an extended conformation, perpendicular to
the plane of the membrane, and indicates a number of interac-
tions unidentified before in ZM241385 recognition. To further
understand the selectivity of ZM241385 for the human A2A
adenosine receptor, we examined the effect of mutating amino
acid residues within the binding cavity likely to have key inter-
actions and that have not been previously examined. Mutation
of Phe-168 toAla abolishes both agonist and antagonist binding
as well as receptor activity, whereas mutation of this residue to
Trp orTyr had onlymoderate effects. TheMet-1773Alamuta-
tion impeded antagonist but not agonist binding. Finally, the
Leu-2493 Ala mutant showed neither agonist nor antagonist
binding affinity. From our results and previously published
mutagenesis data, we conclude that conserved residues Phe-
168(5.29), Glu-169(5.30), Asn-253(6.55), and Leu-249(6.51) play a
central role in coordinating the bicyclic core present in both ago-
nistsandantagonists.Bycombiningtheanalysisof themutagenesis
data with a comparison of the sequences of different adenosine
receptor subtypes fromdifferent species, we predict that the inter-
actions that determine subtype selectivity reside in themorediver-
gent “upper” region of the binding cavity while the “lower” part of
thebindingcavity is conservedacrossadenosinereceptor subtypes.
Extracellular adenosine has an important physiological role
both as a signal of metabolic stress and as a modulator of neu-
rotransmitter release (1, 2). Consequently, adenosine receptors
(ARs),5 members of the G protein-coupled receptor (GPCR)
superfamily of receptors, play a pivotal role in many tissues
throughout the body. Four subtypes ofARs have been identified
in humans, A1AR, A2AAR, A2BAR, and A3AR, and each AR
subtype possesses distinct pharmacological properties, tissue/
cellular distribution, and secondary effector coupling (2).
We recently solved the structure of the membrane-spanning
heptahelical domain of human A2AAR as a fusion protein with
cysteine-free phageT4 lysozyme to 2.6-Å resolution using x-ray
crystallography (3). The structure represents one of the inactive
states of the receptor with the subtype selective high affinity
antagonist ZM241385 (Fig. 1) bound to it, at a relatively low pH
of 5.8. ZM241385 is a selectiveA2AARantagonist that has inter-
mediate affinity for the human A2BAR, a 500- to 1000-fold
selectivity over A1AR, and little affinity for A3AR. The A2AAR:
ZM241385 crystal structure reveals near atomic resolution
details for receptor antagonist interactions, useful in drug dis-
covery applications. Thus, the AA2AR structure-based virtual
ligand screening in a recent study demonstrated a40%hit rate
in identification of novel and diverse lead-like chemotypes for
adenosine receptor antagonists (4). Many residues shown to be
important for ligand binding in previously published mutagen-
esis studies were also shown to have direct contacts with the
bound ligand in the crystal structure. For example, mutations
that have been reported to disrupt antagonist and/or agonist
interactions, Glu-169(5.30), His-250(6.52), Asn-253(6.55), and
Ile-274(7.39), have important ligand binding interactions in the
crystal structure (the numbers in parentheses indicate residue
number based on the Ballesteros-Weinstein nomenclature (5)).
Surprisingly, we found that the binding mode of ZM241385 to
its receptor is very different from the binding of ligand to other
GPCRs with known crystal structures, the beta-blockers timo-
lol, carazolol, and cyanopindolol co-crystallized with turkey
1-adrenoreceptor or human 2-adrenoceptors and retinal co-
crystallized with bovine and squid rhodopsin, and binding of
these ligands to their cognate receptors has very little overlap
with ZM241385 binding to A2AAR when all available receptor
structures are superimposed (6). In addition, the orientation of
ZM241385 in the binding pocket deviates greatly from that of
homology models, which used the rhodopsin structure as a
template (7–8). Therefore, models for ligand-A2AAR interac-
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tions based upon these other GPCR-ligand structures can give
only rough picture of ligand binding (9).
To better understand which of the interactions between
ZM241385 and A2AAR found in the crystal structure are bio-
logically significant, to identify which interactions are specific
to ZM241385 binding and which interactions are also used for
binding other A2AAR ligands, and to predict which regions of
the binding pocket contribute to ligand specificity between AR
subtypes, we have combined site-directed mutagenesis studies,
computer-basedmolecular docking studies, and sequence anal-
ysis of the residues that form the “lower” part of the binding
cavity, including interactions with the triazolotriazine core and
the furan ring of ZM241385. In particular, we focus on residues
shown to be important for ligand binding in the crystal struc-
ture but for which no mutagenesis data has been previously
reported, namely: Phe-168(5.29), Met-177(5.38), and Leu-
249(6.51). In addition, we have extended these studies to better
understand the binding of agonists as well as the antagonist
ZM241385. We characterize both the wild-type receptor and
the mutated receptors for their functional activity (effects on
cAMP production) and their ability to bind not only the sub-
type-selective antagonist ZM241385 but also CGS21680, a sub-
type selective A2AAR agonist, and NECA, a non-selective AR
agonist. Through these studies we confirmed the critical role of
Phe-168(5.29), in the aromatic stacking interaction of the (dif-
ferent) bicyclic cores of typical antagonists and agonists. In
addition, we demonstrate that Met-177(5.38), which interacts
with the furan ring of ZM241385 in the crystal structure, has a
less prominent role in the binding of agonists that lack this
furan group and that mutation of Leu-249(6.51) to Ala has a
surprisingly strong unfavorable effect on both prototypical antag-
onist and agonist binding to the A2AAR. Adding considerations
from sequence analysis and molecular modeling to our observa-
tions, we conclude that the binding surface and interaction of the
“lower” part of ZM241385 and similar antagonists is conserved
between different AR subtypes and species, suggesting that the
interactions that determine subtype selectivity reside in the more
divergent “upper” region of the binding cavity.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis—The plasmid pBac5b830400
A2AAR containing human A2AAR (3) served as wild-type con-
trol and as template for site-directed mutagenesis. Mutagenic
primers were designed to change codons for Phe-168 3 Ala
(gctgcggggagggccaagtggcctgtctcgctgaggatgtggtccccatgaactaca-
tgg)/Trp (gctgcggggagggccaagtggcctgtctctgggaggatgtggtcccca-
tgaactacatgg)/Tyr (gctgcggggagggccaagtggcctgtctctatgaggatgt-
ggtccccatgaactacatgg), Met-1773 Ala (tctttgaggatgtggtcccca-
tgaactacgcggtgtacttcaacttctttgcctgtgtgc), and Leu-249 3 Ala
(tggggctctttgccctctgctggctgcccgcacacatcatcaactgcttcactttcttct)
amino acids (mutations are indicated by underlines).Mutations
were made using site-directed mutagenesis utilizing standard
PCR techniques beginning with an initial denaturing tempera-
ture of 95 °C for 30 s, then 18 cycles of 95 °C for 30 s, 55 °C for 1
min, and 68 °C for 7 min. Subcloning into pcDNA3.1() was
performed using PCR with primer pairs encoding endogenous
FIGURE 1.Set of prototypical antagonist andagonists for humanA2AARused in this study.A, ZM241385, a subtype-selective antagonist for humanA2AAR
(Ki of 260 nM for human A1AR, 0.8 nM for A2AAR, 32 nM for A2BAR, and10,000 nM for A3AR, respectively). B, NECA, a relatively non-selective agonist for human
ARs (Ki of 14 nM for human A1AR, 20 nM for A2AAR, 330 nM for A2BAR, and 67 nM for A3AR, respectively). C, CGS21680, a relatively selective agonist for human
A2AAR (Ki of 290 nM for human A1AR, 27 nM for A2AAR, 361,000 nM for A2BAR, and 67 nM for A3AR, respectively). Dotted boxes in A are as follows: 1, furan ring
extension of ZM241385; 2, bicyclic triazolotriazine core of ZM241385 with exocyclic amino group; and 3, phenoxyethylamino substituent of ZM241385.
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restriction sites BamHI at the 5 (GGA TCC ATG AAG ACG
ATCATCGCCCTGAGCTACATCTTCTG) andHindIII at
the 3 (AAGCTTCTAATGGTGATGGTGATGGTGATG
GTG ATG GTG AGG) termini of pBac5b830400A2AAR
with subsequent ligation into the corresponding restriction
sites found in pcDNA3.1(). All DNA sequences and muta-
tions were verified by automated API sequencing.
Sf9 Baculoviral Overexpression—Recombinant baculovirus
(108 viral particles perml) was prepared according to a stand-
ard transfection protocol from Expression Systems (available
on-line). Briefly, high titer recombinant baculoviruses were
generated by co-transfecting 2 g of transfer plasmid contain-
ing the target coding sequence with 0.5g of SapphireTM bacu-
lovirus DNA (Orbigen) into Spodoptera frugiperda (Sf9) cells
using 6 l of FuGENE 6 transfection reagent (Roche Applied
Science) and Transfection Medium (Expression Systems). Cell
suspension was incubated for 3–4 days while shaking at 27 °C.
P-0 viral stock was isolated after 4 days and used to produce
high titer baculovirus stock. Expression of gp64was detected by
staining with gp64-PE. Viral titers were determined by a flow
cytometric method (10).
Transfection of HEK293T Cells—HEK293T cells were grown
as monolayers in Dulbecco’s modified Eagle’s medium supple-
mented with 2 mM glutamine and 10% newborn calf serum at
37 °C in a moist, 7% CO2 atmosphere. Cells were transfected
with the indicated plasmids usingN-[1-(2,3-dioleooxy)propyl]-
N,N,N-trimethylammonium methyl sulfate (made in-house,
University of Leiden). Experiments were performed 48 h after
transfection.
Flow Cytometric Analysis of Cell Surface Expression and
Total Protein Expression—To detect plasmamembrane-bound
and cytosolic receptors, a flow cytometric expression assay was
performed as previously described (10). Briefly, commercial
monoclonal M2-anti-FLAG antibody (5 g, Sigma-Aldrich) or
monoclonal antibody 856 anti-APJ (7 g, R&D Systems, Min-
neapolis, MN) were conjugated with 26 l of Alexa-488-chro-
mophore (Invitrogen, Eugene, OR) according to the manufac-
turer’s protocol. Alexa-488 conjugated monoclonal antibody
856was diluted 7-fold in Tris-buffered saline (TBS: 20mMTris,
pH 7.5, 150 mM NaCl) containing 4% bovine serum albumin
(BSA), while the Alexa-488 conjugated FLAG antibody was
diluted 10-fold with TBS containing 4% BSA and 0.1% Triton
X-100. To measure expression, 10 l of cell culture was mixed
with 15l of the Alexa-488-antibody-diluted conjugation solu-
tion. The reaction was incubated at 4 °C for 20 min and then
diluted 5-fold with TBS to a final volume of 200 l. The reac-
tions were assayed for fluorescence using a Guava Easycyte
microcapillary flow cytometer (Hayward, CA), utilizing laser
excitation of 488 nm and emission of 532 nm.
Raw Membrane Isolation for Binding Studies and Immuno-
blotting—The following protocols were all carried out on ice or
at 4 °C unless otherwise noted.
Sf9 Cells—Frozen aliquots of cells were thawed and then
resuspended in homogenization buffer (50 mM Hepes, pH 7.4).
The cells were subjected to homogenization using a Nitrogen
Cavitation Pump (30min, 800 p.s.i.) following 30 strokes with a
Dounce homogenizer. The cell debris and nucleolus were
removed by centrifugation at 900  g for 10 min, followed by
centrifugation at 100,000  g for 45 min to isolate the raw
membrane fraction. The resulting membrane pellet was resus-
pended in buffer containing 20 mM Hepes, pH 7.4, 800 mM
NaCl, and the protein concentrationwas assayedusing theBCA
protein assay kit from Pierce using BSA as a standard for the
protein assay.
HEK293T Cells—Cells were detached from the plates by
scraping them into 5ml of phosphate-buffered saline, collected,
and centrifuged at 200  g for 5 min. Cell pellets were resus-
pended in 20 ml of ice-cold 50 mM Tris-HCl buffer, pH 7.4. An
Ultra-turrax was used to homogenize the cell suspension. The
cytosolic and membrane fractions were separated using a high
speed centrifugation step of 100,000 g (31,000 rpm in a Beck-
man Optima LE-80K ultracentrifuge) at 4 °C for 20 min. The
pellet was resuspended in 10 ml of Tris buffer, and the homog-
enization and centrifugation steps were repeated. The resulting
pellet was resuspended in 50 mM Tris-HCl buffer, pH 7.4.
Adenosine deaminase was added to a final concentration of
0.8 IU/ml.
Saturation Isotherm and Competition Binding Experiments
Using Sf9 Membranes—Prior to the ligand binding assays, the
membrane pellets were resuspended in ligand binding buffer
with either a low salt concentration (TME: 50 mM Tris-HCl, 10
mMMgCl2, 0.5 mM EDTA, pH 7.4) or a high salt concentration
(same TME buffer supplemented with 1000 mM NaCl). The
samples were tested for binding with [2-3H]-4-(2-[7-amino-2-
{2-furyl}{1,2,4}triazolo{2,3-a}{1,3,5,}triazin-5-yl amino]ethyl)-
phenol ([3H]ZM241385, 27.4 Ci/mmol), which was obtained
from ARC Inc. (St. Louis, MO). Crude plasma membranes (0.2
g of total protein per reaction) were incubated for 30 min at
room temperature with serial dilutions of the radioligand
(0.05–10 nM). Incubations were rapidly terminated by filtration
using a Tomtec Mach III cell harvester (Tomtec) through a
96-well GF/B filter plate (MultiScreen Harvest plate, Millipore
Corp.), and rinsed five times with 500 l of ice-cold buffer (50
mM Tris-HCl, pH 7.4). The harvest filter plates were dried, and
30l of OptiPhase-HiSafe III scintillation liquid (Perkin-Elmer
Life Sciences) was added. The bound radioactivity was meas-
ured using a PerkinElmer Wallac Jet 1450 Microbeta Scintilla-
tion Counter. Nonspecific binding was determined in parallel
reactions in the presence of an excess of theophylline (100 M,
Sigma-Aldrich), and specific binding was defined as the differ-
ence between total and nonspecific binding. Protein concentra-
tions were determined with the BCA protein assay (Pierce),
using BSA as a reference. All incubations were performed in
triplicate, and independent experiments were repeated at
least two times. Equilibrium dissociation constants (Kd) and
maximal receptor levels (Bmax) were calculated from the
results of saturation experiments using GraphPad Prism ver-
sion 4 software.
For competition binding studies, themembranes were resus-
pended in ice-cold binding buffer (TME: 50 mM Tris-HCl, 10
mM MgCl2, 0.5 mM EDTA, pH 7.4), containing protease inhib-
itors (Complete protease inhibitor mixture tablet, Roche
Applied Science) and homogenized for 30 strokes with a
Dounce homogenizer. Crude plasma membranes (5–20 g of
total protein per reaction) were incubated for 60 min at room
temperature with radioligand [3H]ZM241385 concentration
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close to the equilibrium dissociation constant (2 nM) and using
10–14 different concentrations of the competing unlabeled
ligands. The GTP dependence of agonist binding was investi-
gatedwith the stableGTP analogGpp(NH)p (10M). Reactions
were rapidly terminated by filtration and counted as described
above. All incubations were performed in triplicate, and inde-
pendent experiments were repeated at least twice.
Competition Binding Assays Using HEK293T Membranes—
[3H]ZM241385 (27.4 Ci/mmol) was obtained from ARC Inc.
NECA and CGS21680 were obtained from Sigma. All other
materials were purchased from commercial sources and were
of the highest available purity. Binding assays were performed
in a 100-l reaction volume. The assay mixture contained 50
mM Tris-HCl buffer, pH 7.4, membrane protein (25 g/assay
point for single point assays, 5 g/assay point for competition
curves). The ability of increasing concentrations of the antago-
nist ZM241385 and agonists NECA and CGS21680 to compete
with [3H]ZM241385 for binding to the various A2AAR con-
structs was tested in the absence or presence of 1000 mMNaCl.
Nonspecific binding was determined in the presence of an
excess of CGS21680 (100 M). The radioligand concentrations
were close to equilibrium dissociation constants (Kd 1.0 nM).
Incubation was for 2 h at 25 °C. Binding reactions were termi-
nated by filtration through Whatman GF/B filters under
reduced pressure using a MY-24 cell harvester (Brandell). Fil-
ters were washed three times with ice-cold buffer and placed in
scintillation vials. Radioactivity was determined using a Tri-
Carb 2900TR liquid scintillation analyzer (PerkinElmer Life
Sciences).
Cell-surface Receptor Measurement and Enzyme-linked
Immunosorbent Assay—Transfected cells were seeded in
48-well plates (Costar). After 48 h of incubation, the monolay-
ers were washed once with TBS (50mMTris, 150mMNaCl (pH
7.5)) and fixed for 30 min with 4% paraformaldehyde in phos-
phate-buffered saline. Subsequently, cells were washed three
times with TBS and, where appropriate, permeabilized with
0.5% Nonidet P-40 in TBS. After 30 min, the permeabilization
solution was replaced with blocking buffer (1% fat-free milk,
0.1 MNaHCO3 (pH 8.6)), and the cells were incubated for 4 h at
room temperature. Then, the blocking buffer was replacedwith
the primary antibody solution containing a 1:1000 dilution of
anti-FLAG (M2) antibody (Sigma) in TBS with 0.1% BSA. The
cells were incubated overnight at 4 °Cwith shaking. Themono-
layers were washed three times with TBS, after which the sec-
ondary antibody containing a 1:2500 dilution of Goat-anti-
mouse IgG-horseradish peroxidase conjugate (Bio-Rad) was
added. After 2 h of incubation at room temperature, the cells
were washed three times with TBS and theOPD substrate solu-
tion (5 mM O-phenylenediamine (Sigma), 0.03% H2O2 in 0.1 M
citrate-phosphate buffer (pH 5.0)) was applied for 10 min.
The reaction was stopped by the addition of 1 M H2SO4,
samples were taken from the supernatants, and the optical
density was measured in a Victor2Wallac multilabel counter
at 490 nm.
Demonstration of Downstream Signaling by Intracellular
cAMP Determination—HEK293T cells were grown and trans-
fected as described above. Experiments were performed 48 h
after transfection. Cells were harvested, resuspended in stimu-
lation buffer and added to 384-well OptiPlates at a concentra-
tion of 7500 cells/well. The assay was performed following the
protocol recommended in the LANCE cAMP 384 kit
(PerkinElmer Life Sciences). The assay tracer, antibody, and
detection mix are components of the kit. Deviations from the
kit protocol are as follows. The stimulation buffer used was
phosphate-buffered saline with the addition of 5 mM HEPES,
0.1% BSA, 50 M rolipram, 50 M cilostamide, and 0.8 IU/ml
adenosine deaminase. The assay was performed in white 384-
well OptiPlates (PerkinElmer Life Sciences). Treatment of cells
with agonist or antagonist was for 45min. Following addition of
the detection/antibody mix plates were left for 3 h prior to
reading using a VICTOR2 plate reader (PerkinElmer Life
Sciences).
SDS-PAGE Immunoblotting—Equal amounts of Sf9 total
membranes from the wild-type and mutant samples were sep-
arated on identical 12% SDS-polyacrylamide gels (Pre-Cast
Gels, Bio-Rad Laboratories) and electroblotted using a semi-
dry cell (Bio-Rad Laboratories) to methanol-treated (20 s) and
TBS buffer-soaked polyvinylidene difluoride membranes. The
blots were incubated overnight with 5% fat free milk, TBS
buffer, 0.5% Tween 20. One blot was incubated with mono-
clonal anti-FLAG M2 antibody (Sigma, 1:5,000) in TBS con-
taining 0.5%Tween 20 and 5% nonfat drymilk for 1 h. A second
blot was incubated with monoclonal anti-A2AAR antibody
epitope against the receptor’s third intracellular loop (Milli-
pore, 1:10,000) in the same buffer. Blots were washed 3 20
min with TBS-Tween 20 and then incubated with horserad-
ish peroxidase-conjugated anti-mouse IgG (Amersham Bio-
sciences, 1:50,000) for 1 h. The blots were washed 5 20min
and visualized with an ECL-plus chemiluminescence kit
(Amersham Biosciences).
Docking and Molecular Modeling—The 3EML crystal struc-
ture was used formolecular docking. Two different approaches
were used for adding hydrogens atoms: default parameters for
protonation in the docking programFlexXor from the program
H (available on-line from Virginia Tech). The program
FlexX was used for docking procedures. Residues within a
sphere of 9 Å from ZM241385 were included as belonging to
the binding cavity, otherwise default parameters were used. In
case of mutations, the corresponding side chains were changed
using the program PyMOL and energy-minimized with the
Swiss PDBViewer suite.
Model Refinement and Binding Energy Evaluation—Initial
docking models of ligand-receptor complexes were refined
using ICM conformational modeling (11), and their relative
binding energy was evaluated as described previously (12). The
energy functions included the following ICM terms with the
corresponding default weights: van der Waals (“vw” and “14”),
hydrogen bonding (“hb”), distant dependent electrostatics
(“el”), torsion (“to”), and desolvation term (“sf,” surface tension
of 0.004). The global optimization procedure was performed in
internal coordinates with free torsion variables in the ligand
and the side chains of the binding pocket, as defined by 9-Å
distance from the ligand atoms in the PDB entry 3EML.
Data Analysis—The results were analyzed using Prism
(Version 4.03 or 5.0, GraphPad, San Diego, CA). The values
are mean values  S.E. of at least two independent experi-
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ments performed in triplicate. The
concentrations that inhibited half
of radiolabeled ligand binding
(IC50) and the apparent affinities
(apparentKi) of each ligand for each
receptor variant were determined
by using nonlinear regression anal-
ysis and applying the Cheng-Prusoff
equation (13), assuming one-site
binding. For agonist binding, both
one-site binding and two-site bind-
ing models were tested. The EC50 is
the concentration of agonist that
evoked half of themaximal response
in functional cAMP assays. For
homogeneous competition-based
maximum receptor density (Bmax)
and ligand binding affinity (Kd)
determination, the following equa-
tion was used: Bmax (Bo IC50)/[L],
Kd IC50 [L]; where Bo is specif-
ically bound ligand and L is ligand
concentration.
Ballesteros-Weinstein Nomen-
clature—To compare GPCR family
A members, we have used the Ball-
esteros-Weinstein double-number-
ing system (5). Along with number-
ing their positions in the primary
amino acid sequence, the residues
have numbers in parentheses (X.YZ)
that indicate their position in each
transmembrane (TM) helix (X), rel-
ative to a conserved reference resi-
due in that TM helix (YZ). This res-
idue is arbitrarily assigned the
number 50. However, the number-
ing is not used in the extra/intracel-
lular regions beyond residues
TM.20 or TM.70, as these are highly
divergent loop regions that cannot
be reliably aligned.
RESULTS
Selection of Amino Acid Residues
ofA2AAR for Further LigandBinding
Cavity Analysis—An x-ray crystal
structure analysis of the human
A2AAR-ZM241385 complex re-
vealed 11 residues that are in direct
contact with ZM241385 (Fig. 2).
The PDB-deposited structure (3EML)
reveals that these form 75 atomic
receptor-ligand contacts with a
distance of 	4 Å. Additionally,
ZM241385 makes several atomic
contacts with crystallographic water
molecules. Fig. 3 shows a multiple
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sequence alignment of AR subtypes across a number of species.
The TM domains, including the lower part of the ZM241385-
binding cavity, are highly conserved among receptors from dif-
ferent species (Fig. 3A), and the extracellular domains and
upper part of the ZM241385 binding site are somewhat less
conserved (Fig. 3, A and B). We sub-classified the residues
shown to interact with ZM241385 in the co-crystal structure
into four partially overlapping categories. The first category
consists of residues that interact with the furan ring:
(Leu-85(3.33), Met-177(5.38), Trp-246(6.48), Leu-249(6.51),
His-250(6.52), andAsn-253(6.55)) (Figs. 2C and 3B). These res-
idues aremainly located in TMs 3, 5, 6, and 7 and hold the furan
ring in close proximity to these TMs while stabilizing the
so-called “toggle-switch” Trp-246(6.48) side-chain rotamer in
the inactive conformation. The second category consists of the
residues that make contacts with the bicyclic triazolotriazine
core unit of ZM241385: Phe-168(5.29), Glu-169(5.30),
Asn-253(6.55), and Ile-274(7.39). The third category consists of
the residues that are close to the 4-hydroxyphenyl group of
ZM241385: Leu-267(7.32), His-264(6.66), and Met-270(7.35).
Notably, non-xanthine A2AAR ligands with a ZM241385-like
bicyclic/tricyclic core unit have a large chemical variability in
this third area of the pharmacophore. Furthermore, in the PDB-
deposited model, large atomic temperature factors (B-factors)
are associated with the 4-hydroxyphenyl group of ZM241385,
an indication of local structural flexibility. The fourth category
includes those amino acid residues that make interactions with
crystallographic waters in the structure. The major contribu-
tion to the binding of ZM241385 is derived from residues in
classes one, two, and four (Table 1 and Figs. 2C and 3B). Sur-
prisingly, a literature review reveals that the majority of these
residues has neither been recognized as binding residues in
silico nor studied biochemically such as in mutagenesis exper-
iments (for recent review, see Ref. 14). In the present study we
focused on the first and second categories, selecting amino acid
residues that are in direct contact with ZM241385 but for
which no mutagenesis data is available from the published lit-
erature: namely residues Met-177(5.38); Phe-168(5.29), and
Leu-249(6.51) (Table 1). We examined these by constructing
mutant receptors in which the selected residues were replaced
with alanine or in the case of Phe-168(5.29), with alanine, tyro-
sine, or tryptophan.
Functional Expression of Wild-type and Mutated Receptors—
To verify thatmutated receptors were well expressed and prop-
erly localized to the cell surface, we measured total receptor
levels (SDS-PAGE followed by immunoblotting) in comparison
to the amount of receptor detected on the surface of non-per-
meabilized cells (flow cytometry using fluorescently labeled
anti-receptor antibodies). Wild-type and mutated receptors
were expressed to approximately equal levels in Sf9 baculovirus
cells (Table 2). When transiently expressed in HEK293T cells,
the relative expression levels of the mutant receptors varied as
compared with the wild-type, with Phe-168(5.29) mutants all
having greater expression, and Met-177(5.38)3 Ala and Leu-
249(6.51)3Ala displaying lower expression. Allmutant recep-
tors demonstrated significant cell surface expression, with a
similar fraction of total receptors at the cell surface (0.5–0.6).
Thus, wild-type andmutated receptors were properly localized
on the cell surface in both expression systems (Table 2).
Binding Properties in G Protein-restricted Environment
Using Sf9 Membranes—To evaluate the contributions of
different residues to ligand binding, we examined the satura-
tion binding isotherms of the wild-type and mutated receptors
expressed in Sf9 membranes for a radiolabeled antagonist
([3H]ZM241385).When comparedwith thewild-type receptor,
the Phe-168(5.29)3 Tyr and Phe-168(5.29)3 Trp mutations
showed an 8- and a 4-fold decrease, respectively, in
[3H]ZM241385 binding affinity (Table 3). Mutation of this res-
idue to a small apolar residue, Phe-168(5.29)3Ala, eliminated
binding to [3H]ZM241385. TheMet-177(5.38)3Alamutation
reduced the binding affinity of [3H]ZM241385 by 8-fold and the
Leu-249(6.51) 3 Ala mutant showed no measurable radioli-
gand binding for [3H]ZM241385.
Binding Properties in G Protein-balanced Environment
Using HEK293T Membranes—Sf9 cells represent an essen-
tially G protein-free environment. For analysis of agonist
binding, it is important to use a more native expression sys-
tem for G proteins, such as transient expression in HEK293T
cells. Expression in HEK293T cells also allows determination
of the functional effects of the binding site mutations on
receptor-mediated G protein signaling. To directly compare
the ligand-binding properties of wild-type andmutated A2AAR
expressed in these two different cell lines, we verified that their
ligand-binding properties were similar. A single point radioli-
gand binding assay using a saturating concentration of
[3H]ZM241385 (20 nM) revealed no specific binding to the Phe-
168(5.29)3 Ala or Leu-249(6.51)3 Ala mutated receptors, in
agreement with the data obtained using Sf9 cell membranes.
Receptor densities based on homologous competition binding
assays of [3H]ZM241385 to either wild-type, Phe-168(5.29)3
Tyr, Phe-168(5.29) 3 Trp, or Met-177(5.38) 3 Ala mutated
receptors were measured to be 3.5  0.4 pmol/mg, 0.8  0.1
pmol/mg, 3.4 0.3 pmol/mg and 1.6 0.2 pmol/mg of protein,
respectively (Table 3). The binding affinity of Phe-168(5.29)3
Tyr and Met-177(5.38) 3 Ala mutated receptors for
[3H]ZM241385 determined in homologous competition
FIGURE 2. ZM241385 binding mode and receptor-ZM241385 interactions. A, receptor:ligand:lipid:metal ion backbone representation of the structure of
human A2AAR-T4 lysozyme fusion protein with ZM241385 bound (PDB ID: 3EML). The missing part of extracellular loop 2 is modeled onto the structure
(beginning andendingpoints are indicatedby thedotted red line). The T4 lysozyme fusionprotein domain is omitted from the figure. Themembraneboundary
planes are obtained from the Orientations of Proteins in Membranes database (available on-line from the University of Michigan) and marked as “dummy”
atoms (blue-colored dummy atoms in the cytoplasmic region and red-colored dummy atoms at the extracellular site). The receptor is colored blue at the amino
terminus and changes gradually to red at the carboxyl terminus. Lipid, ligand, and sulfate ions are shown as stickmodels, and their polar interactions are shown
as thinblue lines. Crystallographicwaters in thebindingcavity are shownas redballs.B, extracellular viewof theZM241385-bindingcavity.Normalizedoccluded
surface areaswere calculated for ZM241385 binding residues and are represented as thickened red regionsof the backbone chain. Residues are labeled by their
corresponding Ballesteros-Weinstein indexing. The polar anchoring residues of Asn-253(6.55), Glu-169(5.30), and toggle-switch residue of Trp-246(6.48) side
chains are shown as stick models, and polar interactions with ZM241385 (black) are indicated as light blue dotted lines. C, schematic ligand-plot representation
of the polar and aromatic interactions between ZM241385 and human A2AAR at the antagonist-binding cavity.
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assays was decreased 2- and 4-fold, respectively, as com-
pared with wild-type, whereas only 1.5-fold change in affinity
for [3H]ZM241385 was observed for the Phe-168(5.29)3 Trp
mutant (Table 3). These results are consistent with the mea-
surements obtained from receptors expressed in Sf9 cells,
although the magnitude of the decreased ligand affinity dis-
played by the mutated receptors is more modest in the
HEK293T cells.
We also determined the effects of these binding site muta-
tions on the ability of the agonists NECA or the A2AAR-selec-
tive agonist CGS21680 to compete with [3H]ZM241385 (Table
4). Binding (Ki) of Phe-168(5.29)3Tyr to NECA or CGS21680
was decreased by 13- and 25-fold, respectively, compared with
binding of these ligands to the wild-type receptor. In contrast,
the affinity of Phe-168(5.29)3Trp for NECAwas increased by
at least 2-fold, whereas the affinity of thismutant for CGS21680
was similar to the wild-type (Table 4). Interestingly, the affinity
of the Met-177(5.38) 3 Ala mutant for NECA was similar to
that of the wild-type receptor, whereas the affinity of this
mutant for CGS21680 was decreased by 7-fold. As these two
agonists have identical chemical scaffolds, 5-uronamide aden-
osine, and differ only in the solvent-exposed C2-substituent
that is present in the CGS21680 structure and cannot directly
interactwithMet-177(5.38), this difference in binding affinity is
most likely explained by the higher conformational mobility of
NECA in the binding pocket (see also “Discussion”).
Functional G Protein Response Using cAMP Assay—We
measured receptor activity using intact HEK293T cells tran-
siently transfected with wild-type and mutated receptors. Pro-
totypical A2AAR agonist CGS21680 stimulated adenylyl cyclase
activity mediated by both wild-type and mutated receptors.
When compared with wild-type receptor, the Phe-168(5.29)3
Tyr mutant showed a 4-fold decrease in activity, whereas
mutation of this residue to a tryptophan showed a near wild-
type EC50 value (Table 5). The cAMP assay also revealed
that, although the Phe-168(5.29) 3 Ala mutation resulted
in no detectable binding of the radiolabeled antagonist
[3H]ZM241385 (Table 3), the agonist CGS21680 could still
evoke a response, albeit with a 63-fold lower activity than the
wild-type receptor (Table 5). Similarly, the cAMP assay
revealed that the mutant Leu-249(6.51) 3 Ala resulted in an
11-fold decrease in CGS21680 agonist potency compared with
wild-type (Table 5). Finally, the mutation of Met-177(5.38)3
Ala showed a significant 6-fold decrease in agonist potency
consistent with the competition binding data obtained in
HEK293T cell membranes (Table 4). The presence of endog-
enously expressed A2BAR in HEK293T cells prevents measure-
ment of the potency of the non-selective AR agonist NECA.
Automated Docking—We docked ZM241385, NECA, and
CGS21680 into the crystal structure at a standard protonation
state (as calculated by the H server as well as in the FlexX
program suite, pH 7.0), and two additional protonation states
(pH 5.5 and pH 8.0) (Fig. 4). We used FlexX, which models
side chains as rigid moieties, in default mode. We included
residues within a 9.0-Å sphere around the ZM241385 binding
site without any other constraints (e.g. for a polar interaction
from Glu-169(5.30), Asn-253(6.55), or aromatic interaction
from Phe-168(5.29), and all crystallographic waters were
removed.Without any constraints,95%of the docking results
(top 10 solutions obtained per ligand per pH) showed a polar
interaction between Asn-253(6.55) and the exo-cyclic amino
group of the ligand as well as aromatic stacking interactions
between Phe-168(5.29) and either the triazolotriazine core
(ZM241385) or adenine ring system (NECA, CGS21680) (Fig.
4). Re-docking of ZM241385 showed the largest variation in the
position of the 4-hydroxyphenyl group side chain (Fig. 4A).
Interestingly, in 5% of the docking results for NECA and in 20%
for CGS21680, the ligand was rotated 180 degrees so that the
polar interactions with the receptor via Asn-253(6.55)/Glu-
169(5.30) and aromatic stacking interactions with receptor via
Phe-168(5.29) were approximately correct, but the ribosemotif
was directed toward the extracellular space. In the remaining
docking results for bothNECA andCGS21680, the ribosemotif
interactions were similarly oriented and clustered into two ori-
entations irrespective of the studied protonation states (Fig. 4).
In the first conformation, the ribose motif makes a polar inter-
action with backbone of Ala-81(3.29), and in the second con-
formation it is in close proximity to Ser-277(7.42) and
His-278(7.43). Energy minimization of receptor side chains
revealed that in this conformation the ribose groupmakes polar
interactions with Ser-277(7.42) andThr-88(3.36) (Fig. 4D). The
latter conformation of the ribose ring is likely to be more rele-
FIGURE 3. Amino acid sequence alignment and degree of conservation in the ZM241385 antagonist-binding cavity. A, amino acid sequences of AR
subtypes from different species (rat, mouse, and zebrafish) were aligned with human subtypes. The multiple amino acid sequences were aligned using the
TCoffee algorithm (availableon-line). Identical residues are shaded ingreen,75%conserved residues are shadedpurple,50%are shaded in yellow, and	25%
conserved residues are shown in blue. The three residues examined in this study are indicated by dashed boxes. B, proximal ZM241385-binding cavity:
ZM241385 and side chains of interacting residues are shownas stickmodels; ZM241385 isgray, and the interacting residues are colored as inA; the coloring scale
is shown above the figure. The side-chain variation between human subtypes is denoted.
TABLE 1
Calculated contributions of various A2AAR residues to ZM241385
binding; only residues within 4.5 Å of the ligand are shown
Bold font indicates amino acid residues examined in this study. Mutations that are
reported to disrupt antagonist and/or agonist binding are indicated in italic. Con-
tacts that are unfavorable in the crystal structure and improved in the conforma-
tionally refined model are shown as underlined text. vdW, van der Waals.
Pocket residues Contact distance
Energy
(3EML)
Energy
(refined)
Total vdW Total vdW
Å kcal/mol
Phe-168(5.29) 3.2 6.0 6.0 6.4 6.4
Asn-253(6.55) 3.0 4.7 2.3 5.7 2.4
Leu-249(6.51) 3.5 3.5 3.4 3.1 3.0
Glu-169(5.30) 3.4 4.0 3.0 2.1 1.4
Met-177(5.38) 3.0 1.3 1.3 1.7 1.6
Ile-274(7.39) 3.9 1.8 1.8 1.4 1.5
Met-270(7.35) 3.1 15.9 15.8 1.3 1.3
Leu-85(3.33) 3.7 1.2 1.2 1.1 1.1
Trp-246(6.48) 3.4 0.2 0.2 1.1 1.1
Leu-267(7.32) 3.8 1.4 1.4 0.7 0.7
Asn-181(5.42) 4.4 0.4 0.4 0.5 0.4
His-264(6.66) 3.3 0.1 0.1 0.0 0.1
His-250(6.52)a 3.4 1.9 1.8 0.7 0.6
Totals 6.8 3.4 24.3 20.4
a Interaction is mediated mainly via crystallographic waters.
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vant for the agonist-bound state of the receptor, because both
Ser-277(7.42) and Thr-88(3.36) have been implicated in ago-
nist, but not antagonist binding (15). In silicomutations to Phe-
168(5.29)3 Ala, Leu-249(6.51)3 Ala, and Met-177(5.38)3
Ala followed by docking, suggest that these mutations do not
have a major impact on ligand orientation (Fig. 4D).
Effect of Mutations on Ligand Binding—To understand the
effects of the receptormutations on ligand binding and to iden-
tify docked ligand models that are consistent with the func-
tional behavior of themutated receptors, we performed energy-
based refinement of the ligand receptor-ligand models using
global energy optimization of the ligand and the pocket side
chains in the ICM program (Molsoft, LLC). Refinement of the
ZM241385-A2AAR crystal structure itself yielded only minor
changes in side-chain positions that relieved some steric strain
in the Met-270(7.35) and His-250(6.52) contacts with the
ligand. Predicted total and Van der Waals-only contribu-
tions of each contact residue to the ligand binding energy are
shown in Table 1. This analysis suggests that Phe-168(5.29),
Asn-253(6.55), and Leu-249(6.51) makemajor contributions to
TABLE 2
Expression levels of wild-type andmutated human A2AARs
Immunoblot, flow-cytometry, or ELISA analysis of wild-type and mutant A2AAR on the cell surface of intact cells or on isolated membranes from Sf9 and HEK293T cells.
Sf9
HEK293T, ELISAc
Receptor
construct Immunoblotting
a
Flow cytometryb (% of wild-type)
Without
permeabilization
With
permeabilization
Cell surface
(without permeabilization)
With
permeabilization
Ratio cell surface/
permeabilized cell
Mean fluorescence units % of wild-type with permeabilization
Wild type Single band; 827 (100%) 1085 (100%) 59 4 100 5 0.65
Phe-168(5.29)3 Tyr Single band; 1325 (160%) 1377 (127%) 185 4 307 8 0.62
Phe-168(5.29)3 Trp Single band; 1152 (139%) 1088 (100%) 109 5 180 7 0.64
Phe-168(5.29)3 Ala Single band; 1486 (180%) 1251 (115%) 72 8 116 4 0.66
Met-177(5.38)3 Ala Single band; 1227 (148%) 1218 (112%) 38 1 65 2 0.66
Leu-249(6.51)3 Ala Single band; 1011 (122%) 1023 (94%) 31 4 83 1 0.48
Negative control No band, 180 (22%) 201 (19%) 0 1 2 1
a Immunoblotting was done with anti-FLAG antibodies and anti-A2AAR antibodies using isolated crude membranes. The spot intensity of mutated receptors was visually
compared to wild-type; , strong immunoreactivity indicating high expression in isolated membranes; , clearly detectable immunoreactivity; , detectable immu-
noreactivity; and, no immunoreactivity.
b Flow cytometry was done using anti-FLAG antibodies as primary antibodies and fluorescently labeled antibodies as secondary probes.
c ELISA was done using anti-FLAG antibodies as a probe. Details for immunoblotting, flow cytometry, and ELISA studies are described under “Experimental Procedures”.
TABLE 3

3HZM241385 antagonist binding properties of wild-type andmutated human A2AARs expressed in Sf9 and HEK293T cells
The table showsmean S.E.; minimum two independent experiments, each performed in triplicates. Saturation isotherm binding studies were carried out withmembrane
homogenates prepared from baculovirus-infected Sf9 cells, and homogeneous competition binding experiments were carried out with membrane homogenates prepared
from transiently transfected HEK293T cells as described under “Experimental Procedures.”
Receptor
construct
Saturation binding
characteristics using Sf9 cells
Homologous competition binding characteristics
using HEK293T cells
Kd Kd(mutant)/Kd(wild-type) Bmax
Bmax(mutant)/
Bmax(wild-type) Kd
Kd(mutant)/
Kd(wild-type) Bmax
Bmax(mutant)/
Bmax(wild-type)
nM -fold pmol/mg -fold nM -fold pmol/mg -fold
Wild-type 1.6 0.4 1 38 3 1 2.4 0.8 1 3.5 0.4 1
Phe168(5.29)3 Tyr 13 3 8 16 3 0.4 5.5 0.3 2.2 0.8 0.1 0.2
Phe168(5.29)3 Trp 6.4 0.7 4 15 1 0.3 3.6 0.3 1.5 3.4 0.3 1
Phe168(5.29)3 Ala n.s.b.d.a n.s.b.d. n.s.b.d. n.s.b.d.
Met177(5.38)3 Ala 12 2 8 10 1 0.3 10.4 1.4 4.3 1.6 0.2 0.5
Leu249(6.51)3 Ala n.s.b.d. n.s.b.d. n.s.b.d. n.s.b.d.
a n.s.b.d., no specific binding detected.
TABLE 4
Ligand binding properties of wild-type andmutant human A2AARs characterized in 

3HZM241385 binding assays in competition with NECA
or CGS21680
Table shows mean  S.E.; minimum three independent experiments, each performed in triplicates. Ligand binding affinities (pKi/Ki values) were determined in

3HZM241385 (5–10 nM) inhibition binding experiments using membrane homogenate prepared from transiently transfected HEK293T cells as described under “Exper-
imental Procedures.” pKi/Ki values were calculated by the Cheng-Prusoff equation (Prism 5.0, GraphPad). About 20g of membrane protein per incubation was used. Data
was analyzed using a one-way analysis of variance analysis with a Bonferroni post-hoc test, as in GraphPad Prism 5.
Receptor
construct
Competitor
NECA CGS21680
pKi Ki Ki(mutant)/Ki(wild type) pKi Ki Ki(mutant)/Ki(wild type)
nM -fold nM -fold
Wild type 7.28 0.23 94 61 1 6.49 0.11 357 75 1
Phe-168(5.29)3 Tyr 5.83 0.19a 1190 478 13 5.13 0.17b 8990 3340 25
Phe-168(5.29)3 Trp 7.34 0.18 39 13 0.4 6.38 0.11 534 131 1.5
Phe-168(5.29)3 Ala NDc ND
Met-177(5.38)3 Ala 7.19 0.19 66 31 0.7 5.64 0.09a 2440 526 7
Leu-249(6.51)3 Ala ND ND
a Significant differences in Ki values between the wild-type and each mutant receptor; p 0.01.
b Significant differences in Ki values between the wild-type and each mutant receptor; p 0.001.
cND, not determined because specific binding of [3H]ZM241385 detected was	10% of wild-type values.
Defining the Human A2A AR Binding Site
13040 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 17•APRIL 23, 2010
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 2, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ligand binding, that Met-177(5.38) and Ile-274(7.39) make
moderate hydrophobic contacts with the ligand, and that the
other residues in the binding pocket have a much smaller
impact on ligand binding. It should be noted that the contribu-
tion of His-250(6.52) to ZM241385 binding is mediated mostly
through the structured water molecule (“wa5” in PDB entry
3EML, B-factor 46 Å2), whereas our calculations did not take
this effect into account. More detailed analysis of mutational
effects for Phe-168(5.29), Leu-249(6.51), and Met-177(5.38)
positions was provided by implicit conformational modeling of
modified residues with flexible ligand and receptor side chains.
The results of binding energy predictions for mutant com-
plexes with ZM241385, CGS21680, and NECA are shown in
Table 6. For the Phe-168(5.29) position, although mutations to
non-aromatic residues were predicted to have a dramatic neg-
ative effect on binding, Tyr and Trp side chains were easily
accommodated within the structure and yielded only modest
drops in binding energy, which is in line with experimental
results. For the Leu-249(6.51)mutations, changes to small polar
amino acid (alanine) resulted in a lost hydrophobic contact for
this residue and a significant drop in binding energy for all
ligands. Interestingly, this drop was much less pronounced for
the Leu-249(6.51) 3 Val mutation; valine in this position is
present in the A2BAR subtype. For the Met-177(5.38) position,
the modeling predicts only minor drops in binding energy for
an alanine mutation.
DISCUSSION
The recently solved human A2AAR-ZM241385 co-crystal
structure revealed that the prototypical non-xanthine antagonist,
ZM241385, binds very differently to the receptor than had been
predicted by models based on rhodopsin binding to retinal (7,
8). The long axis of ZM241385 lies orthogonal to themembrane
plane and has a large number of interactions with residues in
TMdomains 5–7, and extracellular loops 2 and 3 (3). The struc-
ture of the extracellular domain (extracellular loops 1–3) has
little secondary structure and is held together by a network of
four disulfide bridges, three of which are unique to ARs (Fig.
2A). This novel and relatively rigid architecture of the extracel-
lular domain, together with the unexpected orientation of the
ZM241385 ligand, shifts the upper parts of the TM helices
when compared with the other known GPCR structures.
Indeed, the binding of ZM241385 is very different from and
almost perpendicular to that of retinal in rhodopsin/opsin or
the beta-blockers timolol, carazolol, and cyanopindolol in the
1- and 2-adrenoceptors.
In particular, the previously published models based on the
rhodopsin structuremisplaced andmisoriented the ZM241385
molecule (and similar types of non-xanthine and xanthine
ligands), in a position resembling that of retinal or the -adre-
noreceptor antagonists. Although newer models based on
2-adrenoreceptor structure were able to predict some of the
key features and receptor contacts for ZM241385 binding, large
scale deviations in extracellular regions of the TMhelices in the
models, as much as 6 Å from the solved crystal structure of
A2AAR, resulted in inaccurate positioning of the ligand and
missed important interactions (for details, see a recent publica-
tion (9)).
ZM241385 is a prototypical AR antagonist, composed of a
core bicyclic triazolotriazine unit (see Fig. 1, notation 2), a
furan ring, and a 4-hydroxyphenylethyl side chain (Fig. 1).
The furan ring system is located deep in the binding cavity. It
may act by helping to keep the receptor in a resting state
through stabilization of Trp-246(6.48), the toggle-switch rota-
mer, in an inactive conformation (Figs. 2 and 3). The central
aromatic/triazolotriazine core systemmakes polar interactions
with the highly conserved Asn-253(6.55) and Glu-169(5.30)
residues and hydrophobic interactions with equally conserved
Phe-168(5.29) and Ile-274(7.39) side chains. The triazolotria-
zine core unit of ZM241385 alsomakes a number of polar inter-
actions with ordered water molecules filling the solvent-ex-
posed part of the open binding cavity (Fig. 2).
The 4-hydroxyphenyl ring system makes largely hydropho-
bic interactions with Ile-267(7.32), Met-270(7.35), and His-
264(6.66) in the upper region of the binding cavity and a polar
interaction with a crystallographic water molecule. Of note are
high crystallographic B-factors in the 4-hydroxyphenyl moiety
(100Å2) pointing to its high conformational flexibility even in
the receptor-bound state. This is in line with previous struc-
ture-activity relationships studies, which established a variety
of substituents in this position for high affinity triazolotriazine-
like antagonists (16–17), as well as low amino acid sequence
conservation of the 4-hydroxyphenyl ring contact residues
between adenosine subtypes and vertebrate species (Fig. 3).
Taken together with the results reported here that demonstrate
the importance of the residues in the lower region of the bind-
ing cavity for the strength of ligand binding, these observations
suggest that interactions in the upper region of the binding
pocket are less important for ligand binding affinity, but rather
contribute to A2AAR ligand specificity.
Some of the above interactions have already been correctly
identified through mutagenesis studies of the human A2AAR
prior to the determination of the crystal structure (2). In par-
ticular, Glu-169(5.30), His-250(6.52), Asn-253(6.55), and Ile-
274(7.39), which are conserved among the vertebrate ARs (Fig.
3), have been directly implicated previously by both mutagen-
esis studies and modeling/structure-activity relationship stud-
ies (15, 18–20). However, the crystal structure also establishes a
TABLE 5
CGS21680-induced agonist stimulation of cAMP production
mediated by wild-type andmutant A2AARs
Agonist CGS21680-induced cAMP production was measured in transiently trans-
fected HEK293T cells as described under “Experimental Procedures.” The table
shows mean  S.E.; minimum two independent experiments, each performed in
triplicates. Data were analyzed using a one-way analysis of variance analysis with a
Bonferroni post-hoc test, as in GraphPad Prism 5.
Construct pEC50 (EC50 nM) Fold (EC50 mutant/EC50WT)
Wild-type 7.63 0.13 (27.5) 1
Phe-168(5.29)3 Tyr 7.00 0.07 (102)a 4
Phe-168(5.29)3 Trp 7.49 0.16 (33.0) 1
Phe-168(5.29)3 Ala 5.84 0.14 (1730)b 63
Met-177(5.38)3 Ala 6.86 0.19 (156)c 6
Leu-249(6.51)3 Ala 6.51 0.05 (314)b 11
a Significant differences in pEC50 between the wild-type and each mutant receptor;
p 0.05.
b Significant differences in pEC50 between the wild-type and each mutant receptor;
p 0.001.
c Significant differences in pEC50 between the wild-type and each mutant receptor;
p 0.01.
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number of interactions unknown before in ZM241385 ligand
recognition, involving eight uncharacterized residues. This
prompted us to evaluate the functional importance of these
residues in non-xanthine and xanthine ligand binding. In this
report, residues Phe-168(5.29), Met-177(5.38), and Leu-
249(6.51), which are located in the lower part of theZM241385-
binding cavity, and not previously reported on, were targeted
for site-directed mutagenesis.
The importance of Phe-168(5.29) to ligand binding had
not been fully recognized prior to the determination of the
crystal structure of A2AAR, although conservation of this
amino acid between all known sequences of AR subtypes/spe-
cies (Fig. 3A) and homology modeling studies provided some
hints for its involvement in ligand binding (15). Our results
demonstrate the essential role of the Phe-168(5.29) side chain
in extracellular loop 2 in ligand binding. Interestingly, based on
normalized occluded surface calculations in the crystal struc-
ture, Phe-168(5.29) has the highest contact area with
ZM241385 and contributes an aromatic-stacking interaction
with the central triazolotriazine unit of ZM241385 (Fig. 2B).
The calculated contribution of Phe-168(5.29) to binding is 6
kcal/mol, or 25% of total binding energy for ZM241385
(Table 1). Furthermore, our radioligand binding and functional
experiments using receptors with mutations at Phe-168(5.29)
show the importance of aromatic stacking and hydrogen bond-
ing to ligand binding. The Phe-168(5.29) 3 Trp mutation
retained wild-type agonist and antagonist-binding properties
and signaling function even though tryptophan has a much
FIGURE 4. Crystallographic structure-based molecular model of the human A2AAR containing “docked” antagonist ZM241385, agonist NECA, and
agonist CGS21680 bound in the antagonist-binding cavity. Only parts of TM3, TM5, TM6, TM7, and a selected set of side chains in these TMs are shown.
A, structural alignment of computationally re-docked ZM241385 (orange) in the experimental-binding cavity of co-crystallized ZM241385 (yellow). The polar
interactions between ZM241385, crystallographic water molecules, and receptor are shown as black dotted lines. Docking was done using the FlexX program,
including rigid side chainswithin 9 Å from the original ZM241385-binding cavity andwith default protonation state (pH 7.0) as described under “Experimental
Protocols.” Note thedifferent orientationof the 4-hydroxyphenyl group extensionof ZM241385. B andC, superimposition of computationally docked agonists
CGS21680 (B, orange) and NECA (C, orange) and co-crystallized ZM241385 (yellow) in the binding cavity. Only the automatic top solution produced by FlexX is
shown. The other solutions alter the position and interactions of the ribosemotif of NECA/CGS21680 and the C2-substituent of CGS21680. In all solutions the
ribose motif is occupying different positions from the furan ring of ZM241385. D, influence of studied Ala mutations on the orientation of ZM241385 upon
re-docking. Re-docked ZM241385 is shown in purple for the Phe-168(5.29) 3 Ala mutant, green for the Met-177(5.38) 3 Ala mutant, and blue for the
Leu-249(6.51)3Alamutant, ZM241385 from the co-crystal structure is shown in yellow. The orientation of the bicyclic core of ZM241385 is similar in all of the
re-docking studies. E, energy minimization of the hypothetical NECA-receptor complex creates polar interactions (black dotted lines) between NECA (orange)
and receptor residues Thr-88/Ser-277.
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bulkier side chain. Our modeling studies (Fig. 4 and Table 6)
show that tryptophan comfortably fits in the A2AAR structure
without major rearrangement of other residues. The mutation
of Phe-168(5.29) to tyrosine, comparable in size and aromatic
stacking properties to phenylalanine but with different hydro-
gen bonding capabilities, modulated agonist binding, antago-
nist binding, and functional properties resulting in a receptor
with a moderately lower affinity for all ligands. In contrast,
mutation of this phenylalanine to alanine resulted in a complete
inability to measurably bind the radiolabeled antagonist
[3H]ZM241385, although intracellular cAMP accumulation
assays reveal that this mutant could still bind the A2AAR ago-
nist CGS21680 and activate receptor-mediated G protein sig-
naling, albeit with a 63-fold lower potency than the wild-type
receptor. These results suggest that the aromatic stacking inter-
actions between Phe-168(5.29) and the heterocyclic core of
“classic” adenosine ligands are essential for both adenosine ago-
nist and antagonist high affinity binding and agonist function.
The second largest normalized occluded surface interface
between receptor residue andZM241385 iswith Leu-249(6.51),
which is calculated to be 70% of the Phe-168(5.29) normalized
occluded surface area (Fig. 2B). Leu-249(6.51) is located almost
opposite to Phe-168(5.29) with respect to ZM241385 and
makes hydrophobic interactions with the central triazolotria-
zine unit of the ligand. However, unlike Phe-168(5.29) the
leucine residue in this position is not absolutely conserved (Fig.
3), with a valine residue occurring in the human A2BAR. This is
suggestive of a size restriction in this position. Although a role
for this residue in ligand binding was suggested by Kim and
co-workers, the specific nature of the interaction was not
described (15). Here, the substitution to the small and less
hydrophobic alanine residue abolished radioligand binding,
suggesting strong structural requirements at this position in the
triazolotriazine-binding cavity. However, in the cAMP accu-
mulation assay a functional response for the agonist CGS21680
was retained for thismutant, although at 10-fold lower potency.
The elimination of ligand binding and reduction of receptor
activity upon mutation of Leu-249(6.51) to alanine suggests
that this residue is vital for high affinity binding of the both the
antagonist ZM241385 and the agonist CGS21680, although the
agonist does retain some functional activity, suggesting that
this residue is not as critical for agonist binding as for antago-
nist binding.
A third previously uncharacterized residue in the lower part
of the ZM241385-binding cavity is Met-177(5.38), which is
conserved throughout the AR family. Based on the crystal
structure, Met-177(5.38) interacts with the furan ring of
ZM241385 and is calculated to have 27% of the Phe-168(5.29)
binding surface. As predicted by thismoremodest contact area,
the alanine mutation only moderately reduced [3H]ZM241385
binding affinity and had no significant effect on the affinity of
the agonist NECA. Intriguingly, the Met-177(5.38) 3 Ala
mutation had a significant effect on both the affinity and
potency (6- and 7-fold respectively) of the A2AAR-selective
agonist CGS21680. As the model of agonist binding in Fig. 4
suggests, the ethylcarboxamide substituent at the C4 position
in the ribose ring of both CGS21680 and NECAmakes a direct
contact with theMet-177(5.38) side chain, explaining themod-
est sensitivity to mutation of this residue. Although NECA is
also predicted tomake this contactwithMet-177(5.38), the lack
of a bulky substituent in the adenine ring of NECA may allow
more conformational flexibility in the receptor. This lackwould
also compensate for the lost contact in the Met-177(5.28) 3
Ala mutant, whereas the bulky substituent on the adenine ring
of CGS21680 limits the conformations accessible to the recep-
tor binding pocket.
Our results suggest that the binding mode of the triazolo-
triazine (antagonist) and adenine (agonist) cores is highly
conserved, with Phe-168(5.29) making important interactions
with both selective and non-selective agonists and antagonists.
In contrast, themutagenesis data alongwith the docking results
suggest that the agonist ribose moiety is not in the same loca-
tion as the furan ring of ZM241385, and that the Met-
177(5.38)-ribose interaction is different from the Met-
177(5.38)-furan ring interaction. It is tempting to speculate that
the very hydrophilic ribose moiety, so important for receptor
activation, would be located where the crystallographic water
network in the lower part of the binding pocket resides, and our
docking studies as well as previously published docking studies
(15) support this localization. In our docking studieswe find the
ribosemoiety in an orientation inwhich significant interactions
are made with residues Thr-88(3.36), Ser-277(7.42), and His-
278(7.43), close to the water network mentioned above. All
three residues have previously been mutated and have been
shown to be critically involved in agonist binding (20–22).
Indeed mutation of Thr-88(3.36) or Ser-277(7.42) results in a
substantial decrease in agonist but not antagonist binding and
potency (22). However, it should be noted that we cannot pre-
dict conformation changes followed by agonist binding.
Furthermore, in one such study a “neoceptor” was generated
bymutation of Thr-88(3.36) to aspartate, which responded to a
positively charged aminosugar agonist derivative, again con-
firming the important interaction between this residue and
agonist ligands (14, 15). However, without an agonist-occupied
structure, it remains unclear to what extent structural rear-
rangements in the binding cavity occur upon binding of an ago-
TABLE 6
Predicted effect of mutations in residues Phe-168(5.29),
Leu-249(6.51), and Met-177(5.38) on free energy antagonist
and agonist binding
Mutation ZM241385
Gbinding
CGS21680
Gbinding
NECA
Gbinding
kcal/mol kcal/mol kcal/mol
Phe-168(5.29) Ala 5.9 5.4 4.7
Val 4.5 5.8 5.0
Tyr 0.3 0.5 0.1
Trp 0.3 0.2 2.7
Leu 5.5 7.3 10.
Met 4.5 9.1 9.4
Leu-249(6.51) Ala 3.3 2.9 3.6
Val 1.2 0.36 1.4
Tyr 14. 56. 7.4
Phe 6.0 23.36 7.8
Trp 74.0 37.3 7.1
Met 0.6 1.7 0.4
Met-177(5.38) Ala 1.4 1.4 1.0
Val 0.7025 0.7453 0.7
Tyr 0.842 0.2536 1.9
Phe 2.486 0.5106 1.9
Trp 6.308 12.04 4.4
Leu 4.047 1.626 0.9
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nist and, consequently, what the exact atomic interactions
would be.
The results of this study validate the key roles of Phe-
168(5.29) and Leu-249(6.51) side-chain interactions with
antagonists such as ZM241385 thatwere observed in the crystal
structure, and demonstrate their equal importance for agonist
binding. This suggests that the heterocyclic scaffold of both
agonists and antagonists interact with the same core group of
residues, and therefore this part of the ligand is in a very similar
position for both agonists and antagonists. The modest selec-
tivity of ZM241385 between A2AAR and A2BAR has risen from
very small amino acid variations in the binding cavity; poten-
tially in positions 6.51 (in lower part of cavity) and 7.32 (upper
part). Clearer differences are seen between A2AAR and A3AR,
where critical positions 5.30, 6.52, and 7.32 differ. Without a
doubt, it would be beneficial to produce more antagonist co-
structures, although an agonist-occupied structure would pro-
vide greater impact. In the absence of a crystal structure of the
A2AAR with an agonist bound, this study provides useful infor-
mation to allow successful ligand docking studies at this recep-
tor for both agonists and antagonists. This information, then,
adds to the knowledge gained from the crystal structure and
will aid in the design ofmore selective ligands for this important
drug target.
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